Moderna Inc (MRNA)

[axelvento]

Moderna has filed with the FDA seeking authorization for a two-dose regimen of its vaccine, called Spikevax, in children ages 6 months to 6 years old. Pfizer has not yet completed its FDA authorization application but its clinical trial tested a three-dose course of the vaccine for children ages 6 months to under 5 years old.


June 14 will be the new meeting date for the FDA and its advisory committee of external experts to discuss Moderna’s EUA request for 6 years through 17 years of age.
June 15 will be the new meeting date for the Moderna EUA request for 6 months through 5 years